Your session is about to expire
← Back to Search
Monoclonal Antibodies
lerodalcibep for Cardiovascular Disease (LIBerate-H2H Trial)
Phase 3
Waitlist Available
Research Sponsored by LIB Therapeutics LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Summary
This trial is testing three injectable medications to lower bad cholesterol in patients with heart disease or at high risk for it. These patients are already on strong cholesterol-lowering treatments. The medications help the body remove more bad cholesterol from the blood.
Eligible Conditions
- Cardiovascular Disease
- Hypercholesterolemia
- High Cholesterol
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
LDL-C reduction from baseline at 12 weeks
Secondary study objectives
Achieved ESC/EAS LDL-C goals
tolerability and safety of each treatment: injection site reactions
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: LIB003 (lerodalcibep)Experimental Treatment1 Intervention
300 mg SC Q4W
Group II: evolocumabActive Control1 Intervention
420 mg SC Q4W
Group III: alirocumabActive Control1 Intervention
300 mg SC Q4W
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
lerodalcibep
2022
Completed Phase 3
~940
Find a Location
Who is running the clinical trial?
LIB Therapeutics LLCLead Sponsor
10 Previous Clinical Trials
4,707 Total Patients Enrolled
Evan A Stein, MD PhDStudy DirectorLIB Therapeutics
5 Previous Clinical Trials
2,063 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger